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Abstract
Glioblastoma multiforme (GBM), the most common and malignant type of glioma, is characterized by a poor prognosis and
the lack of an effective treatment, which are due to a small sub-population of cells with stem-like properties, termed glioma
stem cells (GSCs). The term ‘‘multiforme’’ describes the histological features of this tumor, that is, the cellular and
morphological heterogeneity. At the molecular level multiple layers of alterations may reflect this heterogeneity providing
together the driving force for tumor initiation and development. In order to decipher the common ‘‘signature’’ of the
ancestral GSC population, we examined six already characterized GSC lines evaluating their cytogenomic and epigenomic
profiles through a multilevel approach (conventional cytogenetic, FISH, aCGH, MeDIP-Chip and functional bioinformatic
analysis). We found several canonical cytogenetic alterations associated with GBM and a common minimal deleted region
(MDR) at 1p36.31, including CAMTA1 gene, a putative tumor suppressor gene, specific for the GSC population. Therefore, on
one hand our data confirm a role of driver mutations for copy number alterations (CNAs) included in the GBM genomic-
signature (gain of chromosome 7- EGFR gene, loss of chromosome 13- RB1 gene, loss of chromosome 10-PTEN gene); on
the other, it is not obvious that the new identified CNAs are passenger mutations, as they may be necessary for tumor
progression specific for the individual patient. Through our approach, we were able to demonstrate that not only individual
genes into a pathway can be perturbed through multiple mechanisms and at different levels, but also that different
combinations of perturbed genes can incapacitate functional modules within a cellular networks. Therefore, beyond the
differences that can create apparent heterogeneity of alterations among GSC lines, there’s a sort of selective force acting on
them in order to converge towards the impairment of cell development and differentiation processes. This new overview
could have a huge importance in therapy.
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Introduction
Glioblastoma multiforme (GBM) is the most common and lethal
type of malignant brain tumor, defined as grade IV astrocytoma
(WHO classification) [1]. Despite aggressive multimodal therapies,
such as surgical resection, chemo- and radio-therapy, the median
survival of patients is currently 15 months, according to recently
reported data [2,3], because of rapid tumor recurrence [4,5]. The
term ‘‘multiforme’’ describes the histological features of this tumor,
i.e. the presence of cellular and morphological heterogeneity and
the parallel coexistence of cell populations with different grades of
differentiation [6]. The search for the origin of this heterogeneity,
that characterizes many tumors as well as GBM, has drawn a lot of
interest, also for the important implications it may have in the
therapeutic field. Several cellular mechanisms have been postu-
lated: i) in the clonal evolution model, stochastic genetic or
epigenetic changes confer a selective growth advantage [7], so
tumor cells in a dominant clone possess similar tumorigenic
potential; ii) the cancer stem cell (CSC) model conversely claims a
hierarchical organization of cells, where only a small subset of cells
are tumorigenic and generate heterogeneity through differentia-
tion [6]. These cells are endowed with stem-like properties and
have been isolated from many types of tumors, including GBM,
where they are termed glioma stem cells (GSCs) [8–12]. Although
this model first seemed to be the most reliable, because it provided
an explanation for resistance to both radiation and chemotherapy
and eventual tumor relapse [13,14], recent observations high-
lighted many complexities and uncertainties that undoubtedly
deserve attention (see the recent reviews [15–17]). Several issues
discussed include the robustness of CSC markers (which can lead
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to underestimate the frequency of tumorigenic cells), the variability
of the CSC phenotype between patients and the presence within a
tumor of multiple phenotypically or genetically distinct CSCs that
coexist in a dynamic state, as tumorigenic and non-tumorigenic
states can reversibly interconvert. Ultimately an emerging
consensus in the field assumes that the CSC and the clonal
evolution models can be interacting sources of heterogeneity [17–
19]. Furthermore, in order to define a CSC, the cellular state and
the molecular signature are much more important than the
phenotype [15].
Indeed, at the molecular level multiple layers of alterations may
reflect this heterogeneity: DNA mutations, chromosomal aberra-
tions, loss of heterozygosity (LOH), copy number alterations
(CNAs) and DNA methylation changes provide together the
driving force for tumor initiation and development [20]. Conse-
quently, every single level should be integrated in order to obtain a
comprehensive knowledge on the multiple grades of aberrations
peculiar for GBM [21]. Many GBM-related genomic alterations
have been identified in the past 20 years [20,22–24], but
investigations that focus on the stem-like counterpart are only a
few [25–30]. Overwhelming evidences prove that GSC lines
represent the proper biological cancer model of GBM, as they are
more representative of the respective primary tumor
[27,28,30,31].
Therefore, we deeply examined six already characterized GSC
lines from the genetic and epigenetic point of view, investigating
chromosomal abnormalities, LOH, CNAs and DNA methylation
profiles, searching for a common ‘‘signature’’ specific for the
ancestral GSC population. Indeed, the identification of cytoge-
nomic and epigenomic landscapes of GSC lines is instrumental to
delineate increasingly robust molecular signatures of these
dynamic and complex subpopulations. The results from this and
other similar studies will help to better define new potential
strategies targeting GSC molecular pathways to overcome their
resistance to radio- and chemo-therapy, block their function or
induce their differentiation.
Materials and Methods
Cell Lines, Cell Culture Conditions and Patient Samples
All the cell lines used in this study have already been published.
Glioma stem cell (GSC) lines were isolated from glioblastoma
except one, the G179, which derives from a giant cell glioblas-
toma. GBM2 and GBM7 cell lines were kindly provided by the
National Institute for Cancer Research, Department of Hematol-
ogy-Oncology, Genova (Italy), while G144, G166, G179 and
GliNS2 cell lines were kindly provided by Professor A. Smith of
the Wellcome Trust – Medical Research Council Stem Cell
Institute, University of Cambridge, Cambridge (UK). All the GSC
lines have been extensively characterized for their stem cell
properties (sphere forming assays, evaluation of differentiation
properties, marker expression, in vivo engraftment) [32,33]. Also
the two human foetal neural stem cell lines, CB660 and CB660SP,
derived from the forebrain and the spinal cord respectively, were
kindly provided by Professor A. Smith [34]. These two cell lines
showed a normal female karyotype 46,XX. Cell expansion was
carried out in a proliferation permissive medium composed by
DMEM F-12 and Neurobasal 1:1, B-27 supplement without
vitamin A (Life Technologies Italia, Milan, Italy), 2 mM L-
glutamine (Euroclone S.p.A., Milan, Italy), 10 ng/ml recombinant
human bFGF and 20 ng/ml recombinant human EGF (Miltenyi
Biotec, Bergish Gladbach, Germany), 20 UI/ml penicillin and
20 mg/ml streptomycin (Euroclone S.p.A., Milan, Italy). GSCs
and human foetal NSCs were cultured in adherent culture
condition in T-25 cm2 flasks coated with 10 mg/ml laminin (Life
Technologies Italia, Milan, Italy), in 5% CO2/95% O2 atmo-
sphere.
Formalin-fixed paraffin embedded (FFPE) tissues of GBM
tumors were derived from five-post-mortem GBM specimens and
provided by the Department of Surgical Pathology, S. Gerardo
Hospital, Monza (Italy).
Immunofluorescence
The immunofluorescence assays were performed on all GSC
lines using rabbit anti-CD133 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA; 1:50) and mouse anti-nestin (Millipore, Billerica,
MA, USA; 1:50) as primary antibodies. Cells were placed onto
slides by means of Cytospin, washed with Dulbecco’s modified
phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde
for 15 minutes and treated for 10 minutes with 0.1 M glycine (in
PBS). Slides were incubated 30 minutes at room temperature (RT)
in blocking solution (5% Bovine serum albumin, BSA, 0.6%
Triton X-100 in PBS) and treated for 30 minutes with 70 U/mg
RNAse (Sigma Aldrich, Milan, Italy; 1:30) in blocking solution.
Cells were incubated with the primary antibodies at 4uC
overnight. Then, slides were rinsed with washing buffer (0.3%
Triton X-100 in PBS) and incubated with secondary fluorescent
antibodies and 2.5 mg/ml propidium iodide (PI) for 1h at RT.
Alexa Fluor 488-conjugated goat anti-mouse or anti-rabbit
(Molecular Probes Eugene, OR, USA; 1:200) were used as
secondary antibodies. Alexa Fluor 647-conjugated phalloidin
(Molecular Probes, Eugene, OR, USA; 1:200) was used to
visualize the actin filaments. Then, cells were washed with PBS
and coverslips were mounted using Polyvinyl alcohol mounting
medium (Fluka Analytical, Milan, Italy). Fluorescent cell prepa-
rations were examined using a Radiance 2100 confocal micro-
scope (Bio-Rad, Hercules, CA, USA), evaluating 100 cells for each
sample. Noise reduction was achieved by Kalman filtering during
acquisition.
Conventional Cytogenetics
Metaphase chromosome spreads were obtained using standard
procedures. Briefly, cell cultures were treated with 0.2 mg/ml
Colcemid (Roche, Basel, Switzerland) and then harvested and
incubated with a hypotonic solution of 0.56% w/v KCl for 15
minutes at RT. Then, cells were fixed with fixative solution
composed of 3:1 methanol:acetic acid. The chromosomes were
QFQ-banded using quinacrine mustard (Roche, Basel, Switzer-
land) and slides were mounted in McIlvaine buffer. Slides were
analyzed using Nikon Eclipse 80i fluorescence microscope (Nikon,
Amstelveen, The Netherlands) equipped with a COHU High
Performance CCD camera. The number of metaphases analyzed
depended on the quality of chromosome preparations. The
karyotype was defined according to the guidelines of the
International System for Chromosome Nomenclature 2009 (ISCN
2009). Therefore, only the clonal chromosomal abnormalities were
reported. Structural rearrangement and chromosome gain must be
found in at least two metaphases, whereas chromosome loss must
be present in at least three cells, in order to be considered clonal. A
minimum of 12 and a maximum of 34 metaphases were evaluated
for each GSC line and the analysis was performed on at least 3
different passages.
Fluorescence in situ Hybridization (FISH)
FISH was performed on metaphase chromosome spreads using
whole chromosome painting (wcp) probes. Specifically, Octo-
chrome Chromoprobe Multiprobe System (Cytocell, Cambridge,
UK) was used and the procedures were assessed according to the
(Epi)genomic Signature of GSC Lines
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manufacturer’s protocol. A minimum of 10 metaphases were
evaluated for each specific square.
DNA Extraction from Cell Lines and FFPE Tissues
DNA extraction from cell lines was performed using the Wizard
Genomic DNA Purification Kit (Promega, Milan, Italy), according
to the manufacturer’s protocol. GBM FFPE tissues were processed
for DNA isolation and purification with ReliaPrepTM FFPE gDNA
Miniprep System (Promega, Milan, Italy).
Array Comparative Genomic Hybridization (aCGH)
Sample preparation, slide hybridization and analysis were
performed using Human Genome CGH Microarray, 4x44K
(Agilent Technologies, Santa Clara, CA, USA), according to the
manufacturer’s instructions. Sex-matched commercial DNA sam-
ples (Promega, Milan, Italy) were used as reference DNA during
array-CGH. Data were analyzed as previously described [35].
Briefly, the arrays were scanned at 2 mm resolution using Agilent
microarray scanner and analyzed using Feature Extraction v10.7
and Agilent Genomic Workbench v5.0 software (Agilent Tech-
nologies, Santa Clara, CA, USA). The Aberration Detection
Method 2 (ADM2) algorithm was used to compute and assist the
identification of aberrations for a given sample (threshold = 5; log2
ratio = 0.3). The estimated percentage of mosaicism was calculated
using the formula determined by Cheung SW et al. [36].
Microsatellite Analysis
Loss of heterozygosity (LOH) analysis of chromosome 1p36-
p35, chromosomes 10 and 13 was assessed by means of PCR-
based assays. Amplimers were selected on the basis of their
heterozygosity rate in the population and they are listed in Table
S1. Amplification of each microsatellite was done in 20 ml volume
with 20 ng/ml of genomic DNA, 1X PCR Buffer, 1 mM primers,
200 mM dNTPs, 1.5 mM MgCl2 and 1 unit of AmpliTaq Gold
DNA Polymerase (Applied Biosystems, Carlsbad, CA, USA).
Amplification products were resolved on 6% polyacrylamide gels
and electrophoresed for 5hs at 160V. Gels were stained with 0.1%
ethidium bromide and LOH was determined by visual observa-
tion.
MeDIP-Chip
Methylated DNA immunoprecipitation and chip hybridization
were performed following the guidelines of Agilent Microarray
Analysis of Methylated DNA Immunoprecipitation Protocol
(Version 1.0, Agilent Technologies, Santa Clara, CA, USA).
Briefly, purified genomic DNA was sonicated to fragments of 200–
600 bp in size and 5 mg of sheared DNA was immunoprecipitated
using 50 ml of pan-mouse IgG Dynal magnetic beads (Life
Technologies Italia, Monza, Italy) and 5 mg of 5-methylcytosine
antibody (Eurogenetec, Seraing, Belgium). DNA was eluted and
then purified by phenol: chloroform procedure and precipitated
with ethanol. Neither MeDIPed DNA nor reference DNA were
amplified but they were directly labeled with Cyanine 5- and
Cyanine 3-dUTP nucleotides, respectively, using Agilent Genomic
DNA labeling Kit Plus (Agilent Technologies, Santa Clara, CA,
USA). Labeled DNA was cleaned up using MicroconTM YM-30
columns (Millipore, Billerica, MA, USA) and eluted in Tris-EDTA
(TE) buffer. Cy5- and Cy3-labeled samples were combined in a
single mixture and hybridized onto a 1x244K array for 40hs at
67uC. Microarrays were scanned using an Agilent microarray
scanner and images analyzed with Agilent Feature Extraction
software v10.7. Data were further analyzed by means of Agilent
Genomic Workbench v5.0 software (Agilent Technologies, Santa
Clara, CA, USA). The full list of CpG islands (CGIs) analyzed is
based on the UCSC Genome Browser hg18, NCBI build 36.1,
March 2006. Data were further analyzed according to the
methodological approach conceived by Dr. Ravid Straussman
and colleagues in 2009 [37].
Pyrosequencing Analysis
Pyrosequencing experiments were aimed at quantitatively
evaluate the methylation levels of the CpG-containing regions of
MGMT and PDGFB genes. The assays were designed to
investigate the same regions covered by MeDIP-Chip probes
and encompassed 10 and 5 CpG sites for MGMT and PDGFB,
respectively. The primers used were the following: MGMT: Fw 59
– GTTTYGGATATGTTGGGATAG –39, Rw 59biotin –
CRACCCAAACACTCACCAAA - 39, Seq: 59 – GATAGTTY-
GYGTTTTTAGAA –39; PDGFB: Fw 59- GGGGGGCGAAGG-
TAATGA –39, Rw 59biotin – CATAAATCGCTAC-
TAAACGCTCTTCCTATCT - 39, Seq: 59 –
ATGAAGAATTAGTTTTAGT –39. PCR reactions were carried
out using 20 ng of bisulphite-converted DNA from G144, G166
and CB660 cell lines in a final volume of 50 ml, with 10 pmol of
forward and reverse primers, one of them being biotinylated.
Quantitative DNA methylation analyses were performed using the
Pyro Mark ID instrument in the PSQ HS 96 System (Biotage AB,
Uppsala, Sweden), with the PyroGold SQA reagent kit (Biotage
AB, Uppsala, Sweden) according to the manufacturer’s instruc-
tions. Raw data were analyzed using the Q-CpG software v1.0.9
(Biotage AB, Uppsala, Sweden), which calculates the ratio of
converted C’s (T’s) to unconverted C’s at each CpG, giving the
percentage of methylation. For each sample, the methylation value
represents the mean between two independent PCR and
pyrosequencing experiments.
Gene Expression
Total RNA was extracted using the TRI Reagent solution
(Applied Biosystems, Carlsbad, CA, USA). RNA was reverse-
transcribed with SuperScript TM II Reverse Transcriptase (Life
Technologies Italia, Monza, Italy) according to manufacturer’s
instructions. For RT-PCR, amplifications were performed with
130 ng of RT product per reaction and 0.15 units of Platinum Taq
DNA Polymerase High Fidelity (Life Technologies Italia, Monza,
Italy), using a Mastercycler instrument (Eppendorf, Hamburg,
Germany). PCR conditions used to detect constitutive HPRT and
PTEN expressions were as follows: 3 minutes at 94uC, followed by
40 cycles at 94uC for 30 seconds, annealing at 62uC for 30
seconds, extension at 72uC for 1 minute, followed by a final
extension at 72uC for 5 minutes. All the PCR products were
electrophoresed on 1.6% agarose gels and stained with ethidium
bromide. Sets of primers used to amplify HPRT and PTEN genes
are listed below: PTEN 59-CGAACTGGTGTAATGATATG -39;
59- CATGAACTTGTCTTCCCGTC -39 (330 bp); HPRT 59-
AATTATGGACAGGACTGAACGTC -39; 59-
CGTGGGGTCCTTTTCACCAGCAAG -39 (388 bp).
Quantitative real-time PCR was performed using an Applied
Biosystems 7500 Standard instrument (Applied Biosystem, Carls-
bad, CA, USA) with gene-specific primers for WNT9A and
WNT11genes (RT2 qPCR SYBR Green-based primers, SA-
Bioscience, Milan, Italy). Reactions were performed according to
manufacturer’s guidelines.
Bioinformatic Analysis
The Gene Ontology (GO) analysis was performed using GOstat
software (http://gostat.wehi.edu.au/) [38], in order to identify
possible enrichment of functional groups, related to ‘‘biological
(Epi)genomic Signature of GSC Lines
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process’’, in a specific input list of genes. GOstat software output
file is a list of p-values for each GO term, estimating the
probability that the observed counts could have occurred by
chance. In order to limit the number of GO terms, a class should
comprise more than five genes to be considered for further analysis
[39]. GO terms were divided in cancer-relevant functional
categories: 1. cell cycle; 2. cell death and apoptosis; 3. response to external
stimulus; 4. cytoskeleton organization; 5. cell signaling; 6. development &
morphogenesis; 7. cell differentiation; 8. immune response; 9. cell motility; 10.
metabolism; 11. transcription & gene expression; 12. intracellular transport;
13. DNA repair & chromatin remodeling. Each category was associated
to a frequency, which was calculated evaluating the ratio between
the number of genes linked to a specific category and the total
number of genes associated with at least one GO term. The
pathway analysis was generated using the Ingenuity Pathway
Analysis software (IPA, Ingenuity System, Redwood City, CA,
USA, www.ingenuity.com). IPA software examines functional
relationship within an input list of genes and identifies the
pathways from the IPA library of canonical pathways that were
most significantly associated with the dataset. The significance of
the association between the data set and the canonical pathway
was measured in 2 ways: 1) a ratio of the number of molecules
from the data set that map to the pathway divided by the total
number of molecules that map to the canonical pathway is
displayed; 2) Fisher’s exact test was used to calculate a p-value
determining the probability that the association between the genes
in the data set and the canonical pathway is explained by chance
alone. Network analysis displays regulatory relationships existing
among the genes in the input dataset and then the involved
networks are ranked by score. Networks are selected if their score
is higher than 3, which means that there’s less than 1/1000 chance
that the clustering would have occurred by chance.
Statistical Analysis
Statistical analysis was carried out performing chi-square test, by
means OpenEpi software v2.3.1, available on line at http://www.
openepi.com/. The critical level of significance was set at p,0.05.
Results
The stemness properties of the GSC lines were monitored
during this study (although they were previously characterized
[32,33]), in order to ensure that the data obtained could be
ascribed to the stem cell subpopulation of GBM. All the GSC lines
retained a good proliferation rate, ability to form neurospheres
(data not shown) and did not enter the differentiation program, as
shown by the stable expression of stem cell markers (CD133 and
nestin, Figure S1) in a rather constant percentage of cells.
Cytogenomic Complexity of GSC Lines
Chromosome analysis was performed for all the six GSC lines
and composite karyotypes (cp) were reconstructed. In addition,
three out of six GSC lines (GBM2, G166 and GliNS2) were
further analyzed by means of FISH, using a panel of whole
chromosome painting probes. In this way, it was possible to
identify recurrent structural abnormalities, which were not
identified by conventional cytogenetic techniques (Table 1 and
Figures S2, S3, and S4). Array CGH analysis was also performed
for all cell lines (Table S2, S3, S4, S5, and S6) except for G144,
whose genomic aberrations were previously reported [33]. The
data discussed in this publication were deposited in NCBI’s Gene
Expression Omnibus [40] and are accessible through GEO Series
accession number GSE41875.
All the clonal chromosomal abnormalities pointed out by this
analysis are listed in Table 1. As expected, each cell line showed a
certain degree of karyotype complexity which ranges from a high
number of structural abnormalities, as the GBM2 cell line, to the
presence of two subpopulations with a different modal number of
chromosomes, as the G179 cell line (G179 and G179*). The modal
number of chromosomes varied from near-diploid (G166,
GliNS2), near-triploid (GBM2, G179), near-tetraploid (G144,
GBM7), to near-pentaploid (G179*). All the chromosomes were
involved in numerical alterations (Figure 1A): the most common
(73% of the total analyzed metaphases) was gain of chromosome 7,
with at least two supernumerary copies in four cell lines (GBM2,
GBM7, G179 and G144, Table 1). Other commonly observed
numerical changes were: loss of chromosome 13 (43%); loss or
gain of chromosome X (28% or 21% of cases, respectively); loss of
chromosome Y (39%); loss of chromosome 10 (in three out of six
cell lines, frequency of 32%). A total of 59 different clonal
chromosomal aberrations were found among the 6 cell lines.
Chromosome 1 was the most involved in structural abnormalities:
the ever present deletions in 1p36-1p33 were further accompanied
by inversions or unbalanced translocations (Table 1 and Figures
S2, S3, and S4). Also chromosomes 18, 11 (three out of six cell
lines), 12 (four out of six cell lines) were frequently damaged by
structural abnormalities. Finally, the long arm of chromosome 6
was affected by loss of genomic material in two cell lines (GBM2
and G166) or by two translocations, involving chromosome 7
(GBM2) or 3 (GliNS2). Lastly, by conventional cytogenetic
techniques, it was possible to observe the presence of double
minutes, which should not be included in the count of the number
of chromosomes. The molecular karyotypes showed some
common genomic features of GBM, such as complete loss
(nullisomy) of 9p21.3 locus (GBM2, GBM7, G179 and GliNS2),
containing CDKN2A and CDKN2B genes (Figure 1B and Tables
S2, S3, S4, S5, and S6). Complete or nearly complete gain of
chromosome 7 was evidenced in the same GSC lines, while for
G166 cells gain of 7p22.3-q11.2, including EGFR, was observed
(Figure 1B and Table S4). Loss of whole chromosome 10 in GBM7
and G179 cell lines led to the inevitable absence of PTEN and
DMBT1 genes and the same alteration was obtained in GliNS2
cells through the loss of 10q21.3-q26.3 region (Table S6).
Accordingly, loss of PTEN locus (10q23.31) resulted in the lack
of detectable PTEN transcriptional expression in G179 and
GliNS2 lines and slight expression in GBM7 cells. Considering the
absence of genomic alterations at PTEN locus in GBM2 and G166
cell lines, the divergences in gene expression should be ascribed to
differences in the methylation levels of PTEN promoter region:
G166 cells revealed PTEN expression and lack of promoter
methylation, while GBM2 cells displayed no PTEN expression and
promoter methylation (Figure S5). Loss of whole chromosome 13,
containing RB1 gene, was evidenced in 86% of GBM2 and 29%
of G179 cells (Table S2 and S5, respectively). Several CNAs
affected chromosome 1: whole p-arm loss nearly in 50% of G179
cells; 1p36-p34 loss in GBM7 and GliNS2 cell lines; 1q21.1-q32.2
gain in G166 (almost 90% of cells); in particular, gain of 1q32.1
locus, containing MDM4 gene, was found also in GBM2 cells.
Other aberrations were: gain of 20p and 20q in GBM7 and G166
cells; loss of chromosome Y in four cell lines. In addition, ‘‘private’’
alterations were evidenced, such as the gain of whole chromosome
X in G166 line, the amplification of 4q12, containing PDGFR and
the loss of TP53 locus (17p13.2-p13.1) in almost 60% of cells in
GBM2 line.
(Epi)genomic Signature of GSC Lines
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Loss of Heterozygosity (LOH) Analysis
LOH analysis was performed using a panel of microsatellites,
spanning on regions mainly involved in GBM pathogenesis.
Microsatellites for chromosomes 10 and 13 were found mainly
heterozygous (data not shown). Microsatellite analysis of chromo-
some 1p revealed segmental LOH in all the cell lines (Figure 1C).
Discontinuous loss was defined as interstitial or small terminal
deletions at one or more loci, with retention of heterozygosity at
the proximal end of the evaluated region, with or without
retention of heterozygosity at the distal end [41]. Precisely, LOH
was discontinuous in G144 and G166 cell lines; interstitial in G179
and GliNS2 cell lines; and telomeric in GBM2 and GBM7. The
D1S214 microsatellite in 1p36.31 was deleted in all the six GSCs
analyzed and it maps in the open reading frame of Calmodulin
binding transcription activator 1 (CAMTA1) gene.
Epigenomic Landscape of GSC Lines
As DNA methylation is a key component of genome regulation
in normal and cancer tissues, we evaluated the methylation status
of three GSC lines. The array platform used in this study covers
27800 CGIs of the human genome [42] and all the data
(percentages and frequencies) are referred to the total number of
CGIs included in the array. Raw data were processed as described
in the material and methods section and they were deposited in the
NCBI’s Gene Expression Omnibus [40] and are accessible
through GEO Series accession number GSE41824. GSC data
were compared with methylation levels of two foetal neural stem
cell (NSC) lines, which were considered as matching normal
control cells: CB660 derived from human foetal forebrain, and
CB660SP isolated from human foetal spinal cord [34]. Addition-
ally, data were compared with DNA methylation status of an
equimolar pool of genomic DNA from GBM FFPE tissues and an
equimolar amount of genomic DNA from peripheral blood
lymphocytes of six healthy male donors (PBL pool), used an
unrelated type of tissue. Results were plotted on a chart showing
CGI methylation or unmethylation frequencies and mean
genomic values were calculated (Figure 2A). Considering the
global DNA methylation data, an overall CGI hypomethylation of
GSC lines was noticed compared to foetal NSCs derived from the
spinal cord, CB660SP (CGI methylation was lower than 50%). On
the other hand, the global CGI methylation percentages of GSCs
were similar to CGI methylation levels of foetal forebrain NSCs
that showed half the CGI methylation content in comparison with
CB660SP cells (35.4% vs. 61.1%, respectively). GBM FFPE tissues
showed a CGI methylation level of 49%, which differs significantly
from the G166 one, but not from those of GBM2 and G144 cell
lines. PBL pool exhibited low level of methylation (26.3% of
methylated CGIs); however, this percentage has already been
reported in literature [43]. Going into deep the distribution of CGI
methylation across the genomic regions was analyzed. Even if, the
overall CGI methylation levels of GSCs, FFPE GBM tissues and
CB660 forebrain NSCs were similar, almost a doubling in the CGI
methylation percentages in promoter and divergent promoter
regions was noticed in GBM2, G144 and GBM FFPE tissues
related to CB660 cells (Figure 2B and Table S7).
As the methylation or unmethylation of promoters is associated
to a specific biological effect (repressing or allowing transcription,
respectively), whereas the methylation of other functional genomic
regions remains controversial [44,45], we deepened our analysis
only for promoter regions. We investigated the methylation status
of selected genes, whose hypermethylation is specifically associated
to GBM: RASSF1A, CDKN2A, MGMT, RB1, CDH1 and
EMP3 (Table S8) [46]. These genes showed a heterogeneous
pattern of methylation among the GSC lines and were mainly
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Figure 1. Cytogenomic profiles of GSCs. (A) Frequency of gains and losses of whole chromosomes in the six GSC lines analyzed by QFQ-banding.
The frequencies of numerical aberrations specific for each chromosome were calculated from the total of the analyzed metaphases of the six cell lines
and represented as mean values. (B) Composite array CGH profiles of GSC lines. (C) Detailed 1p LOH mapping of GSC lines. A common region of LOH
was identified in all the six GSC lines, involving D1S214 microsatellite, located at 1p36.31 and highlighted by the square box.
doi:10.1371/journal.pone.0057462.g001
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methylated in the GBM FFPE tissues rather than in the GSC lines.
Thus, in order to identify a ‘‘GSC-specifically methylated genes’’
signature we compared the CGI methylation status of GSC lines,
GBM FFPE tissues and foetal NSC data. We identified 27 gene
promoters methylated in all three GSC lines and FFPE GBM
tissues and unmethylated in both the foetal NSC lines (Table S9A).
Moreover, this comparison also pointed out 10 genes exclusively de
novo methylated in GSC lines and not in GBM FFPE tissues related
to NSCs, delineating a subgroup of genes exclusively methylated in
GSCs (Figure 3 and Table S9B).
Validation of MeDIP-Chip Analysis
In order to validate MeDIP-Chip results, pyrosequencing of two
genes (MGMT and PDGFB) was performed on G144, G166 and
CB660 cell lines. MeDIP-Chip experiments showed that MGMT
promoter was methylated in these three cell lines. We scored as
methylated the MGMT promoter of G144 and CB660 lines,
whereas G166 displayed an intermediate methylation level (Figure
S6A).
Regarding the methylation status of PDGFB promoter, the
pyrosequencing analysis confirmed the MeDIP-Chip data: in
particular, G166 and CB660 resulted unmethylated for this
region, while G144 was methylated (Figure S6B).
Moreover, we checked the correlation between promoter
methylation, identified by array analysis, and gene expression
(WNT9A and WNT11 genes). In both cases an increased
expression was evidenced in unmethylated gene promoters
compared with methylated ones (Figure S7).
Functional Annotation and Pathway Analysis
Genome-wide data were analyzed through GOstat and IPA
software in order to identify biological functions and pathways
related to input gene lists, respectively. Cancer-related GO terms
were grouped in different functional categories, as described in the
materials and methods section. Each category was scored based on
its own percentage of genes belonging to that specific category [47]
and normalized to the total number of genes. Cell signaling and
development and morphogenesis were the most represented biological
functions in gain and loss regions, which underlie a de-regulation
of genes related to these categories by amplification or deletion of
genomic regions (Figure 4A). Moreover, other categories resulted
affected by CNAs, i.e. cell cycle, apoptosis, cell differentiation, response to
Figure 2. Methylation profiles. (A) Frequency of methylation and unmethylation of CGIs for each sample. The methylation status for each
chromosome is reported and global genomic methylation percentages are displayed as the mean values of all chromosomes values. GSCs vs.
CB660SP *p,0.05, **p,0.01, GSCs vs. GBM FFPE tissues 1p,0.01, Chi-square test. Abbreviation: Met, methylation; Unmet, unmethylation. (B)
Distribution of methylated and unmethylated CGIs among the different functional genomic regions.
doi:10.1371/journal.pone.0057462.g002
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stimulus and cytoskeleton organization. Furthermore, even if at lower
frequencies, cell motility and immune response categories were
associated with deleted regions (Figure 4A).
In order to define a kind of stem-cell genomic signature of
GBM, we compared aCGH data from GSC lines to CNAs derived
from 430 genomic profiles described in literature studies [20,48–
51] obtained from both surgical specimens and serum-cultured cell
lines derived from GBM, so they may be considered as a bulk
tumor genomic signature. Although several new ‘‘exclusive’’
affected regions emerged from our GSC line profiles (Table
S10), unfortunately none of these regions was shared among them.
Anyway, we analyzed through IPA software the genes mapping in
these ‘‘exclusive’’ affected regions in order to identify shared
networks and pathways. Specifically, genes located in these
apparently divergent and ‘‘exclusive’’ affected regions were strictly
associated into interconnected networks, describing a strong
functional relationship converging towards a common mechanism
of de-regulation between the GSC lines (Figure 4B). In Figure 4C
were reported the specific pathways affected by the ‘‘exclusive’’
CNA regions and identified by IPA analysis (see also Table S11).
Similarly, DNA methylation data were analyzed through these
bioinformatic tools. Firstly, the analysis of gene promoters with the
same methylation pattern among GSC lines showed an enrich-
ment of terms related to the metabolism category, with a prevalence
of unmethylated gene promoters (Figure 5A). Increased levels of
unmethylation were found in other two categories: transcription &
gene expression, which could lead to the activation of cancer-related
genes, and in cell cycle, showing the de-regulation of cell
proliferation in GSCs. On the other hand, GSCs showed a
prevalence of methylated terms associated to development &
morphogenesis and nervous system development & differentiation, showing
an impairment of the developmental and differentiation processes.
Cell death & apoptosis showed a balance between methylated and
unmethylated gene promoters, thus epigenetic changes in these
genes might act in order to maintain the malignant ‘‘homeostasis’’
of tumor cells. Conversely, four categories were involved only in
unmethylated gene promoters (intracellular transport, DNA repair and
chromatin remodeling, immune response and response to stress) perhaps
increasing the potential malignant phenotype of GSCs. The
analysis of gene promoters with the same methylation pattern
among GSC lines through IPA software revealed the involvement
of several cancer-related pathways (Figure 5B, Table S12).
Curiously, two pathways had already been identified from the
previous analysis of ‘‘exclusive’’ CNA regions (regulation of eIF4 and
p70S6K signaling and ephrin receptor signaling), indicating that genomic
and epigenomic alterations converge in the same direction.
Secondarily, the analysis focused on 27 gene promoters which
constitute the ‘cancer de novo methylated genes’, as they were
aberrantly methylated in GSC lines and GBM FFPE tissues
compared with foetal NSC lines (Figure 3 and Table S9A). A
strong enrichment of neurodevelopmental process related genes
was evidenced. To achieve a deeper insight into the mechanisms
underlying DNA methylation in GBM, we evaluated if these 27
cancer-specifically methylated genes were targeted by Polycomb
repressive complex 2 (PRC2) in embryonic stem (ES) cells [52].
We found that 13/27 (48.1%) genes were targeted by Suz12
protein, a subunit of PRC2 and such enrichment was statistically
significant (10% of genes are marked by PRC2 complex in ES
cells, Fisher’s exact test, p,0.001) [52]. Lastly, the comparison of
CGI methylation in GSCs, total GBM tissues (FFPE GBM pool)
and foetal NSCs allowed the identification of 10 genes exclusively
methylated in the stem cell subpopulation of GBM (Figure 3 and
Table S9B). Moreover, these genes showed prevalence in the
neural determination and differentiation processes and 3 genes
(TWIST1, ISL2 and SIM2) were targeted by the PRC2 in ES
cells.
Discussion
Towards the Delineation of a Cytogenomic and
Epigenomic ‘‘Signatures’’ Specific for GSCs?
A fundamental issue regarding GSC is the uncertainty of GSC
markers, to the extent that the derivation of robust signatures
describing the GSC subpopulations has become almost the Holy
Grail of research. Indeed, tumors may harbor multiple phenotyp-
ically or genetically distinct CSCs, as we verified in GBM [25],
thus it will be necessary to target not only all the GSC subsets
within a tumor, but at the same time the non-tumorigenic cells, for
their ability to revert to a tumorigenic state [15]. The recent ‘‘back
to Darwin’’ model for cancer propagation, suggested by Greaves
in 2010, assumes cells with variable self-renewal potential or ‘‘stem
cells’’ as the genetically diverse units of evolutionary selection [19].
Taking this model into consideration, we applied an integrated
analysis on six GSC lines, considering them in their entirety from
the genetic and epigenetic point of view in order to achieve a
comprehensive insight into the cytogenomic and epigenomic
landscapes of GBM. The data collected in this work emphasize the
importance of studying GBM, but the observations can be
extended to other types of cancer, by analyzing them entirely at
different molecular levels, like the layers of an onion. Indeed, we
found several canonical cytogenetic alterations of GBM, such as: i)
partial or whole gain of chromosome 7, leading to gain of EGFR
gene (7p11.2), identified in all six GSC lines and associated with
approximately 40% of GBMs [20] (Table 1, Figure 1A and 1B); ii)
loss of chromosome 13, associated with RB1 gene loss, a tumor
suppressor gene localized at 13q14 and deleted in 30% of GBM
cases [53]; iii) nullisomy of 9p21 locus, including CDKN2A and
CDKN2B genes, is linked to a poor prognosis, as the lack of these
negative regulators of cell cycle affects p53 and Rb pathways as
well [54]; iv) loss of chromosome 10, encompassing PTEN gene at
10q23. Considering this last example, anyone can appreciate the
usefulness of our multi-level analysis. Indeed, although 2/5 cell
lines (GBM2 and G166) showed no damage in PTEN pathway at
least at the cytogenetic level, PTEN expression was identified in 2/
5 cell lines (GBM7 and G166) (Figure S5). So, where cytogenetics
is unable to explain, cytogenomics and epigenomics come to
rescue, because the low level of PTEN expression in GBM7 can be
ascribed to the mosaic level of loss of this region (58% of cells),
while the lack of expression in GBM2 cell line can be caused by
the hyper-methylation of PTEN promoter (Figure S5). Another
common alteration (30% of astrocytomas) is 1p deletion [55],
identified in all the cell lines analyzed, both at the cytogenetic and
genomic levels (Table 1 and Figure 1B), suggesting the presence of
a tumor suppressor gene [56]. Although this region is quite large
Figure 3. GSC epigenetic signature. Epigenetic comparison between GSC, NSC and GBM FFPE tissue methylation profiles. The inner circle shows
the 378 shared methylated genes in GSC lines, while the middle circle points out 37/378 genes that were unmethylated in NSC lines. The external
circle displays the methylation status in GBM FFPE tissues. Note that 10 of the 37 specifically methylated genes in the GSC lines and unmethylated in
foetal NSC lines were unmethylated in GBM FFPE tissues, representing the GSC epigenetic signature. The asterisk identifies 27 ‘‘cancer de novo
methylated genes’’ in GSC and GBM FFPE tissues vs. foetal NSCs (see also Table S9A).
doi:10.1371/journal.pone.0057462.g003
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Figure 4. Functional characterization of cytogenomic landscapes. (A) Categories of genes determined by GO analysis and included in gain
and loss regions. Each category is associated to a percentage of frequency which was calculated on the ratio between the number of genes
associated to a specific category and the total number of genes associated to at least one GO term. (B) Tree topology of overlapping network
established using IPA software. Genes in new ‘‘exclusive’’ gain and loss regions identified in GSCs profiles of aCGH were assigned to gene networks
which were strictly interconnected one to each other and revealed cancer-relevant annotations. Different genes can be grouped in several networks,
underlying the same mechanism (i.e. cancer or cell cycle). (C) New ‘exclusive’ CNA region-associated pathways. Each pathway is associated with a p-
value (calculated by Ingenuity Pathway Analysis, IPA, software), which represents the probability that such association could have occurred by
chance.
doi:10.1371/journal.pone.0057462.g004
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(1pter-p32) and the cytogenetic breakpoints are variable, we
identified a minimal deleted region (MDR) at 1p36.31 in all six
GSC lines by means of microsatellite analysis, including CAMTA1
gene, (Figure 1C). This MDR overlaps the 1p MDRs described in
gliomas [41,56] and neuroblastomas [57]. CAMTA1 gene was
found down-regulated in CSCs compared with NSCs [58],
meanwhile its up-regulation reduced colony formation in GBM
cells both in vitro and in vivo, so its functional haploinsufficiency
seems to be associated with a proliferative advantage [59].
Ultimately not considering all the well-known CNAs relating to
GBM (a kind of bulk tumor genomic-signature), our cytogenetic-
genomic analysis didn’t evidence any new alteration shared among
the six GSC lines, defeating our efforts to delineate a GSC
genomic-signature. However, on one hand our data confirm a role
of driver mutations for the CNAs included in the GBM genomic-
signature, on the other it is not obvious that the new CNAs are
passenger mutations, as they may be necessary for tumor
progression specific for the individual patient. If we stopped at
this level of observation it would be like looking closely at the crop
circles, losing the overall design that can be appreciated only
through an aerial view. In fact, at a first level of complexity each
tumor can perturb individual genes via multiple mechanisms (see
above the example of PTEN gene) and a pathway can be damaged
at different levels (genomic, genetic and epigenetic). On the other
hand the picture becomes much more complicated when one
considers that cellular networks contain functional modules and
that tumors target specific modules critical to their growth.
Through our approach, we were able to demonstrate that different
combinations of perturbed genes can incapacitate each module.
The same concept has been proposed using a network-based
approach by Cerami et al (2010) [60]. This new overview could a
have huge importance in therapy as it could explain the CSC
resistance to targeted inhibition. Interestingly, as reported for
other types of cancers [61], it has been recently demonstrated that
GBM therapeutic resistance to EGFR inhibitors may be explained
by compensatory activation of EGFR-related family members
(ERBB2, ERBB3), and therefore simultaneous shutdown of
multiple ERBB family members may be required for more
effective GBM therapy [62]. For example, we decided to better
investigate the cytogenomic and epigenomic states of IFNB1-
STAT3 signaling. Signal transducer and activator of transcription
3 (STAT3) activation is crucial in the maintenance of GSCs: it is
upregulated in GBM and has an anti-apoptotic role [63].
Upstream of STAT3 is interleukin (IL)-6 and IL-6 receptors are
preferentially expressed in GSCs [64]. Moreover, recent evidence
in vitro have also documented a role for IFNB1 that reduced GSC
proliferation via STAT3-mediated differentiation into oligoden-
drocytes [65]. In addition, IFNB1 in vitro treatment reduced levels
of miR-21, one of the most commonly upregulated miRNAs in
glioma, via STAT3 activation. Looking at our data, 4 over 5 GSC
lines had loss at 9p21, where IFNB1 is localized. G166 line didn’t
loose IFNB1, but 85% of cells showed gain at 17p11.2-q25.3,
resulting in the gain of the downstream signaling genes STAT3
and miR-21. Curiously, the same G166 line had 90% of cells that
carried a gain at 1q21, where IL-6R-alfa is located. In this way,
although with different mechanisms, the signaling is damaged,
because on one hand the loss of IFNB1 might cause the non-
activation of STAT3 and consequently the non-inhibition of miR-
21, leading to the block of differentiation and apoptosis. On the
other hand gain of IL-6R, STAT3 and miR-21 could lead to the
same effect, as endogenous IFNB1 may be insufficient to ensure
the functionality of the pathway. Ultimately, beyond the differ-
ences that can create apparent heterogeneity of alterations in GSC
lines, there’s a sort of selective force acting on them in order to
converge towards the impairment of cell development and
differentiation processes.
Functional Analysis Confirmed the Impairment of GSC
Developmental and Differentiation Processes
Functional annotation analysis of gene set identified in CNA
regions of GSCs confirmed an impairment of cellular development
and differentiation processes. Indeed, developmental regulators
may support the malignant phenotype and the stem-like cell
properties, including robust self-renewal potential, shifting the
balance towards the maintenance of an undifferentiated pheno-
type [66,67]. We identified some functional annotations specific
for the stem cell properties of GBM cells. Among the highly
ranked pathways can be found: NF-kB signaling; inflammatory
cytokines signaling pathways (IL-10 and IL-6); integrin and ephrin receptor
Figure 5. The GSCs’ methylation profiles evidence the func-
tional impairment of cell development and differentiation
processes. (A) Functional annotation analysis of commonly methylat-
ed or unmethylated gene promoters in all the three GSC lines (GBM2,
G144 and G166), performed using GOstat software. The graph shows
the percentage (y-axis) of each category compared to totally annotated
genes. (B) Top 10 pathways influenced by DNA methylation pattern in
GSCs. A p-value (calculated by the Ingenuity Pathway Analysis, IPA,
software) is associated to each pathway; this value represents the
probability that such association could have occurred by chance.
doi:10.1371/journal.pone.0057462.g005
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signaling pathways. Thus, genomic analysis may help in the
identification of specific signaling pathways, which play essential
functional roles in cancer stem-like cells [68].
Epigenomic modifications, such as DNA methylation, are an
integral part of the molecular determinants which contribute to
malignancy [69]. The comparison between CNAs and DNA
methylation patterns at promoter regions in GSC lines showed
that aberrant methylation occurred both in regions affected by
CNAs and in regions not affected by these alterations. Thus,
methylation changes in gene promoters seemed to be unrelated to
aberrant copy number [70]. Our data show, for the first time to
our knowledge, the genome-wide methylation profiles of the stem
cell subpopulation of GBM. Analyzing the global GCI methylation
content, GCSs and GBM FFPE tissues showed GCI hypomethy-
lation compared to foetal NSCs isolated from the spinal cord
(Figure 2). Anyway, forebrain NSCs could be a more appropriate
control tissue for GSCs, considering their origin and the molecular
pathways involved in the two cell populations [71]. Thus, even if
global CGI methylation didn’t seem to differ severely from one cell
type to another, a deeper insight actually revealed a doubling of
CGI methylation in promoter regions of GSCs and GBM FFPE
tissues compared with CB660 cells. Promoter hypermethylation is
frequently noticed in cancer as it contributes to tumorigenesis
through the downregulation of tumor suppressor genes or genes
normally involved in cell development and differentiation [46]. So,
at the epigenetic level the differences in the methylation status of
promoter regions may indicate a sort of ‘‘master’’ alteration that
could influence the differentiation properties of GSCs. Anyway,
DNA methylation profiles were heterogeneous, preventing the
detection of a univocal behavior, so further insights will be needed
in order to clarify this issue.
The specific pattern of promoter methylation shared by the three
GSC lines enabled the identification of key biological functions
related to the methylation profiles. Metabolism was the most enriched
function, as cancer cells may require fast cellular turnover,
according to their high replicative phenotype [31]. Transcription
and nervous system development and differentiation were the other top
ranking categories, suggesting that neurodevelopmental genes may
be crucial for the full-stem like phenotype of glioma cells [72].
Pathway analysis showed that only two molecular signaling were
shared between genomic and methylation profiles. Genetic and
epigenetic changes are generally mutually exclusive in a given
tumor [73] and they act synergistically on several signaling
pathways, contributing together to tumorigenesis [74].
The analysis of the methylation status of GSC lines and GBM
FFPE tissues in comparison with NSCs identified 27 ‘‘cancer de
novo methylated genes’’ (Table S9A and Figure 3). These genes
were found mainly involved in transcription and cellular neurodevelop-
mental processes. Moreover, 48.1% of these genes were identified as
Polycomb group targeted (PCGT) genes in ES cells [52] and
similar data were previously reported in a large series of GBMs
[75]. In this study the differences between GSCs and NSCs were
highlighted, because they could indicate which errors may deviate
cancer stem cells from the correct program of differentiation. This
analysis pointed out 10 more genes exclusively and aberrantly de
novo methylated in GSC lines compared with NSC lines. These
genes could be considered a sort of stem cell CGI hypermethyla-
tion signature associated to GBM (Table S9B and Figure 3). In
particular, these genes encode for structural neuronal (CACNA1E,
ECEL1, NEFL, SYT10, STAC2) and neural differentiating
proteins (ISL2, SIM2, TWIST1), cancer-related factors (PTPRK
and TWIST1) and a ribosomal protein (RPL26L1). Furthermore,
3 out of 10 were epigenetically regulated by PRC2 in ES cells
(TWIST1, ISL2 and SIM2), suggesting an important role of
methylation events on these genes affecting cell differentiation
processes and cancer [76–78]. Thus, considering all these data the
Polycomb connection should be strongly supported. In ES cells,
PcG (Polycomb group) proteins reversibly repress genes encoding
transcription factors involved in development and differentiation,
forming the so called ‘‘bivalent domains’’ [79,80]. De novo
methylation at promoter regions of these genes may lock cells in
a stem cell phenotype and promote aberrant clonal expansion
[81,82] in GBM development [81]. Indeed, aberrant methylated
genes in GSCs were highly enriched in terms related to nervous
system development and neurogenesis. Thus, an accumulation of a
subpopulation of cells unable to differentiate can occur and novel
transforming aberrations (both genetic and epigenetic) can be
further acquired [83]. The involvement of PCGT genes in many
types of cancers stresses the importance of this developmental gene
class in tumorigenesis, highlighting a kind of conserved aberrant
methylation pattern in cancer cells which might be considered a
sort of epigenetic hallmark [84,85].
In conclusion, the investigation of multiple levels by genome-
wide profiles is a valuable tool to identify the molecular landscapes
specific for the stem-cell counterpart in GBM and other types of
cancers. This study pointed out the aberrant methylation of cancer
and stem cell relevant genes associated with GBM and thus this
analysis could be the starting point for future works in order to
understand stem cell properties of GBM cancer cells. Moreover,
the impairment of cell development and differentiation of GSCs
stresses the importance of a differentiation-inducing therapy in the
eradication of the stem cell subpopulation in GBM.
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